Insider Spends HK$478k Buying More Shares In EuroEyes International Eye Clinic
Insider Spends HK$478k Buying More Shares In EuroEyes International Eye Clinic
Whilst it may not be a huge deal, we thought it was good to see that the EuroEyes International Eye Clinic Limited (HKG:1846) VP of Denmark & Executive Director, Jannik Jørgensen, recently bought HK$478k worth of stock, for HK$4.90 per share. However, it only increased their shares held by 1.6%, and it wasn't a huge purchase by absolute value, either.
儘管這可能不是什麼大問題,但我們認爲很高興看到丹麥歐眼國際眼科診所有限公司(HKG: 1846)副總裁兼執行董事詹尼克·約根森最近以每股4.90港元的價格購買了價值47.8萬港元的股票。但是,它僅增加了1.6%的股份,按絕對價值計算,這也不是一次巨額收購。
EuroEyes International Eye Clinic Insider Transactions Over The Last Year
EuroEyes國際眼科診所去年的內幕交易
The Founder Jörn Jörgensen made the biggest insider purchase in the last 12 months. That single transaction was for HK$7.8m worth of shares at a price of HK$5.19 each. That means that even when the share price was higher than HK$4.95 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
創始人約恩·約爾根森進行了過去12個月中最大規模的內幕收購。這筆單筆交易是價值780萬港元的股票,每股價格爲5.19港元。這意味着,即使股價高於4.95港元(最近的價格),內部人士也想購買股票。從那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。對我們來說,考慮內部人士爲股票支付的價格非常重要。如果他們支付的費用高於當前價格,通常會更令人鼓舞,因爲這表明即使在更高的水平上,他們也看到了價值。
In the last twelve months insiders purchased 1.78m shares for HK$9.1m. On the other hand they divested 5.00k shares, for HK$29k. In total, EuroEyes International Eye Clinic insiders bought more than they sold over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去的十二個月中,內部人士以910萬港元購買了178萬股股票。另一方面,他們以2.9萬港元的價格剝離了5.00萬股股票。總體而言,EuroEyes國際眼科診所內部人士的購買量超過了去年的賣出量。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
EuroEyes International Eye Clinic is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
EuroEyes國際眼科診所並不是業內人士唯一買入的股票。因此,來看看這份包含內幕買入的成長型公司的免費名單吧。
Insider Ownership Of EuroEyes International Eye Clinic
EuroEyes 國際眼科診所的內部所有權
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. EuroEyes International Eye Clinic insiders own 58% of the company, currently worth about HK$949m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
許多投資者喜歡查看公司內部人士擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。EuroEyes國際眼科診所內部人士擁有該公司58%的股份,根據最近的股價,目前價值約9.49億港元。內部人士的這種重要所有權通常會增加公司爲所有股東的利益而經營的機會。
What Might The Insider Transactions At EuroEyes International Eye Clinic Tell Us?
EuroEyes 國際眼科診所的內幕交易會告訴我們什麼?
The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about EuroEyes International Eye Clinic. That's what I like to see! Of course, the future is what matters most. So if you are interested in EuroEyes International Eye Clinic, you should check out this free report on analyst forecasts for the company.
最近的內幕收購令人振奮。對去年交易的分析也使我們充滿信心。除了較高的內部所有權外,該分析還表明,內部人士對EuroEyes國際眼科診所相當看好。這就是我喜歡看到的!當然,未來才是最重要的。因此,如果你對EuroEyes國際眼科診所感興趣,你應該查看這份關於該公司分析師預測的免費報告。
But note: EuroEyes International Eye Clinic may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:EuroEyes國際眼科診所可能不是最好的買入股票。因此,來看看這份投資回報率高、債務低的有趣公司的免費清單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。